Clinical trial
A Randomized Phase 2 Study of Vincristine Versus Sirolimus to Treat High Risk Kaposiform Hemangioendothelioma (KHE).
NCT02110069 is registered in ClinicalTrials.gov with Boston Children's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase 2 Study of Vincristine Versus Sirolimus to Treat High Risk Kaposiform Hemangioendothelioma (KHE).
- Lead sponsor
- Boston Children's Hospital
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- June 14, 2017
- Completion date
- October 27, 2020
- Enrollment
- 4 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
kaposiform hemangioendothelioma (khe), kasabach-merritt syndrome, tufted angioma